FDA Granted Fast Track Status to Lung Cancer Drug
The designation for TRE-515 aims to accelerate development for patients with a specific non-small cell lung cancer mutation.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Should the government expedite the regulatory approval process for experimental cancer drug combinations?
The U.S. Food and Drug Administration has granted Fast Track designation to the investigational drug TRE-515. This status, intended for patients with G12C mutation-positive non-small cell lung cancer previously treated with chemotherapy and anti-PD-(L)1 therapy, may expedite development and review timelines.
Why it matters
Fast Track status facilitates more frequent communication with the FDA and potential eligibility for Accelerated Approval and Priority Review. It focuses on patients whose cancer has progressed despite standard treatments, addressing a critical need for new therapeutic options in this population.
The FDA issued a Fast Track designation for TRE-515, a drug that inhibits deoxycytidine kinase, to be used in combination with KRAS inhibitors. The impact on clinical outcomes for this patient population is currently being studied.
The players
U.S. Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals and public health in the United States.
Trethera Corporation
A Los Angeles-based biotechnology company focused on developing metabolic-based cancer therapies.
The details
TRE-515 is an oral capsule designed to block deoxycytidine kinase, an enzyme involved in the nucleoside salvage pathway that tumor cells may use to survive the metabolic stress induced by KRAS inhibitors. By targeting this metabolic support system, the drug aims to enhance the effectiveness of concurrent KRAS-targeted therapies. This approach is specifically being developed for lung cancer tumors harboring the G12C mutation.
Timeline
Trethera received a $2.7 million NIH grant in 2025.
The FDA granted Fast Track designation for TRE-515 on October 01, 2026.
Health Landscape
This development represents a strategic effort to overcome treatment resistance in non-small cell lung cancer by targeting alternative metabolic pathways. It sits within a broader shift toward combination therapies that attempt to bypass tumor survival mechanisms used when primary drivers like KRAS are inhibited.
If you or a loved one are managing G12C mutation-positive lung cancer, this designation is a regulatory milestone to track as the drug moves through clinical development. Specific treatment eligibility and the timing of clinical trials are complex decisions best discussed with your oncologist.
The takeaway
The FDA's decision aims to speed up the development of a potential new treatment path for patients with persistent lung cancer. Keep an eye on clinical trial databases if you are interested in experimental therapies for this specific mutation.
Further reading
For more on the current landscape of lung cancer research and treatment, visit our Cancer section.
Live Poll
Should the government expedite the regulatory approval process for experimental cancer drug combinations?
